[A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Thirty-eight adults including 24 males and 14 females with acute nonlymphocytic leukemia were treated with DATV (Daunorubicin, Cytarabine, 6-thioguaninum, Vincristine) regimen from December 1987 to May 1991. The median age was 31 years old (range 13-54). The DATV regimen consisted of DNR 60 mg/day IV for 3 days; Ara-C 100 mg by continuous infusion every 12 hours for 7 days; 6-TG 150 mg PO for 7 days and VCR 2mg IV on day 1.


RESULTS
Complete remission (CR) was achieved in thirty-three of 38 patients after 1-2 courses (mean 1.3) with CR rates 86.8%. Five patients had no response to the regimen. Twenty-four of 33 patients who achieved CR are still in CR for 1-41 months with a median follow-up of 10 months.
Lou
F D
FD
PLA General Hospital, Beijing.
Zhou
Q
Q
Meng
F Y
FY
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D013866:Thioguanine; D003630:Daunorubicin